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Abstract
Background: GPRC6A is a widely expressed orphan G-protein coupled receptor that senses extracellular amino acids,
osteocalcin and divalent cations in vitro. The physiological functions of GPRC6A are unknown.
Methods/Principal Findings: In this study, we created and characterized the phenotype of GPRC6A
2/2 mice. We observed
complex metabolic abnormalities in GPRC6A
2/2 mice involving multiple organ systems that express GPRC6A, including
bone, kidney, testes, and liver. GPRC6A
2/2 mice exhibited hepatic steatosis, hyperglycemia, glucose intolerance, and insulin
resistance. In addition, we observed high expression of GPRC6A in Leydig cells in the testis. Ablation of GPRC6A resulted in
feminization of male GPRC6A
2/2 mice in association with decreased lean body mass, increased fat mass, increased
circulating levels of estradiol, and reduced levels of testosterone. GPRC6A was also highly expressed in kidney proximal and
distal tubules, and GPRC6A
2/2 mice exhibited increments in urine Ca/Cr and PO4/Cr ratios as well as low molecular weight
proteinuria. Finally, GPRC6A
2/2 mice exhibited a decrease in bone mineral density (BMD) in association with impaired
mineralization of bone.
Conclusions/Significance: GPRC6A
2/2 mice have a metabolic syndrome characterized by defective osteoblast-mediated
bone mineralization, abnormal renal handling of calcium and phosphorus, fatty liver, glucose intolerance and disordered
steroidogenesis. These findings suggest the overall function of GPRC6A may be to coordinate the anabolic responses of
multiple tissues through the sensing of extracellular amino acids, osteocalcin and divalent cations.
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Introduction
GPRC6A is a recently identified member of family C of G
protein-coupled receptors (GPCRs) that is most closely related to
the calcium-sensing receptor CASR [1,2,3]. Structural homologies
and conservation of specific domains in members of this family of
receptors suggest an evolutionary link between extracellular
calcium and amino acid-sensing [4,5,6]. Indeed, GPRC6A has
recently been shown to sense extracellular cations and amino acids
and to require both extracellular cations and amino acids for
optimal stimulation in vitro [3]. This dual sensitivity of GPRC6A to
both divalent cations and amino acids is analogous to the related
receptor CASR [7]. Compared to CASR, much higher extracel-
lular calcium concentrations are needed to activate GPRC6A
[3,8], and some studies suggest that cations may only be allosteric
modulators of GPRC6A [9], whereas others show cation-
dependent activation of GPRC6A [3]. The calcimimetic NPS-
R578, an allosteric modulator of CASR [10,11,12], and
osteocalcin, a bone derived calcium binding protein, both enhance
the functional responses of GPRC6A to extracellular calcium in
vitro [3]. The physiologically relevant ligands for and biological
function of GPRC6A remain to be determined [13].
GPRC6A is broadly expressed in many tissues and organs,
including lung, liver, spleen, heart, kidney, skeletal muscle, testis,
brain and bone [1,2,3,14]. The amino acid, osteocalcin, and
divalent calcium ligand specificity of this receptor and its wide
tissue distribution implicate GPRC6A multiple processes. For
example, GPRC6A may be a candidate for the elusive
extracellular calcium-sensing mechanism known to be present in
osteoblasts [3,15,16,17,18], which respond to high local Ca
2+
concentrations (in the range of 8 to 40 mM)[19], amino acids and
osteocalcin in the bone microenvironment. GPRC6A is also a
candidate for the putative osteocalcin receptor regulating energy
metabolism [20]. To determine the function of GPRC6A, we
created mice lacking this receptor. We found a complex
multiorgan, metabolic-like syndrome in GPRC6A
2/2 mice that
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e3858suggests that GPRC6A is involved in nutritional pathways
coordinating the metabolic activity of multiple tissues in response
to changes in extracellular amino acids and divalent cations.
Results
Creation and Gross Phenotype of GPRC6A Deficient Mice
We selectively deleted exon 2 of the mouse GPRC6A gene
(Fig. 1A). Wild-type GPRC6A
+/+, heterozygous GPRC6A
+/2, and
homozygous GPRC6A
2/2 mice were genotyped by PCR (Fig. 1B)
and each genotype was found to be born at the expected
Mendelian frequencies from heterozygous breeding pairs, howev-
er, breeding pairs consisting of GPRC6A
2/26GPRC6A
2/2 had
litter sizes that were roughly half that of GPRC6A
2/26GPRC6A
+/+
or GPRC6A
+/2 and GPRC6A
+/2 breeding pairs, respectively (Data
not shown). In addition, full-length GPRC6A transcripts and
proteins were documented to be absent from various tissues of
GPRC6A
2/2 mice by RT-PCR (Fig. 1C) and Western Blot
(Fig. 1D). GPRC6A
2/2 mice (as well as heterozygous GPRC6A
+/2
mice) were similar in gross appearance, body weight and body
length to wild-type littermates (data not shown). There were no
identified abnormalities in gait or physical activity between wild-
type and GPRC6A
2/2 mice.
GPRC6A Deficiency is Associated with Testicular
Feminization and Reduced Testosterone Levels
On closer inspection, we noted that male GPRC6A
2/2 mice had
feminization of the external genitals (Figs. 2A–C). In 16-week-old
male mice, the genito-anal distance (Figs. 2A and B) as well as
testicular size (Fig. 2C), weight (Fig. 2D) and the weight of seminal
vesicle (Fig. 2E) were significantly reduced in GPRC6A
2/2
compared to wild-type littermates. No histological abnormality
of the testes was noted in GPRC6A
2/2 mice (Fig. 2F). GPRC6A was
highly expressed in Leydig cells, and was also expressed in sertoli
cells, spermatogonia and spermatids by in-situ hybridization
analysis (Fig. 2F, lower panel). We also found abnormalities of
mammary glands in male GPRC6A
2/2 mice, as evidence by
greater ductal outgrowth in the mammary fat pad (in 10/14
GPRC6A
2/2 compared to 3/13 mice wild-type male mice)
(Fig. 2G) and increased the mammary fat pad mass (Fig. 2H).
We found no evidence of embryonic lethality or reduced fertility in
homozygous null male or female mice when bred to their
respective wild-type mates; however we observed a reduced litter
size from breeding pairs consisting of both male and female
homozygous null mice.
Next, we compared the serum testosterone and estradiol
concentration in 16-week-old mice wild-type and GPR6CA
2/2
mice. Testosterone concentrations in male GPRC6A knockout mice
were significantly lower and the estradiol concentrations were
significantly higher in male GPRC6A
2/2 mice compared to wild-
type littermates (Table 1). Estradiol levels were not different
between wild-type and GPRC6A
2/2 female mice, although the
circulating testosterone levels were lower in female GPRC6A null
mice (Data not shown).
Since inactivation of the androgen receptor is reported to lower
testosterone levels in mice [21,22,23], we examined if loss of
GPRC6A lowered androgen receptor expression. We observed no
difference in the amount of AR transcripts in the testis and bone
marrow by RT-PCR (Fig. 3A). Real-time RT-PCR also failed to
demonstrate any difference in AR expression between GPRC6A
null and wild-type mice (Fig. 3B). To explore the possibility that
the reduction in testosterone was due to increased aromatase-
Figure 1. Generation of GPRC6A knockout mice. (A) GPRC6A knockout targeting strategy. (B) Mouse genotyping by PCR shows the presence of
exon 2 in wild-type (GPRC6A
+/+) and its absence in homozygous GPRC6A knockout (GPRC6A
2/2) mice. RT-PCR analysis (C) and Western Blot analysis
(D) of GPRC6A expression in kidney from GPRC6A
+/+ and GPRC6A
2/2 mice. RT-PCR condition, primer set and anti-mGPRC6A antibody are described in
Materials and Methods.
doi:10.1371/journal.pone.0003858.g001
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aromatase gene (Cyp19a1) expression by real-time RT-PCR. The
quantitative real-time PCR using primers located in exon 4 and
the interface between exons 4 and 5 failed to document any
difference in the expression of Cyp19a1 in GPRC6A null mice testis
(Fig. 3C). We did, however, detect a small increase in aromatase
(CPY19) protein levels in testis of GPRC6A
2/2 mice by Western
Blot analysis (Fig. 3D) that was localized by immunhistochemistry
(Fig. 3E) to Leydig cells, sertoli cells, and spermatocytes site where
CPY19 is known to be expressed [24]. Aromatase protein level was
slightly increased by approximately 11% in testis of GPRC6A
2/2
male mice (Fig. 3D). The significance of these changes in
explaining the alterations in the testosterone and estradiol levels
are uncertain, since we did not measure aromatase enzyme
activity.
We found no reductions in the expression of P450 17a-
hydroxylase gene (Cyp17), an enzyme that converts pregnenolone
to dehydroandrosterone (DHEA) in the testosterone synthesis
pathway [25], or estrogen sulfotransferase gene (EST/Sult1e1),
which catalyzes the sulfoconjugation and inactivation of estrogens
[26], in the GPRC6A
2/2 male mice testes by real-time PCR
(Figs. 3G and H). Similarly, aromatase and Sult1e1 were not different
in brain, fat, liver and pituitary of GPRC6A deficient and wild-type
mice (data not shown). Furthermore, serum follicle-stimulating
hormone (FSH) and luteinizing hormone (LH) levels in male mice
were not significantly different between wild-type and the
GPRC6A
2/2 male mice (Table 1). Gonadotrophin-releasing
hormone gene (GnRH) message expression in the brain, however,
was not altered in GPRC6A null mice (Figs. 3H and I).
Abnormalities in Renal Function in GPRC6A
2/2 mice
We previously demonstrated that GPRC6A is highly expressed in
the kidney [3]. We extended these observations by showing that
GPRC6A is expressed in both proximal and distal tubules by in situ
hybridization (Fig. 4A). Interestingly, the expression of sodium-
phosphate cotransporter, NaPi IIa, (both the protein (Fig. 4B) and
Figure 2. Characterization of reproductive system of male GPRC6A
2/2 mice. (A) Gross appearance of male GPRC6A
2/2 mice. The genito-anal
distance is demarcated by arrows. (B) Comparison of the genito-anal distance in 16 week-old GPRC6A
+/+ and GPRC6A
2/2 male mice. (C) Gross
appearance of testes of male GPRC6A
+/+ and GPRC6A
2/2 at age of 16 week-of-age. Upper panel shows testis and epididymis (magnification 106) and
lower panel shows dissected testis (magnification 206) viewed under dissecting microscope. (D and E) Comparison of testicular weight (D) and
seminal vesicle weight (E) in 16 week-old GPRC6A
+/+ and GPRC6A
2/2 mice. (F) H&E stained sections of testicular histology (upper panel; 2006
magnification) and in-situ for GPRC6A in the testis (lower panel; 4006magnification) from GPRC6A
+/+ and GPRC6A
2/2 mice. The arrow heads depict
sites of high GPRC6A expression in Leydig cells, and the arrows indicate that GPRC6A is also expressed in lower amounts in sertoli cells,
spermatogonia and spermatids. (G) Mammary gland abnormalities in male GPRC6A
2/2 mice at 16 week-old. (H) Comparison of mammary fat pad
mass in 16 week-old male GPRC6A
+/+ and GPRC6A
2/2 mice. Data represent the mean6SEM from 6 to 10 mice in each group. * indicates a significant
difference from GPRC6A
+/+ and GPRC6A
2/2 mice at p,0.05, respectively.
doi:10.1371/journal.pone.0003858.g002
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2/2
mice, suggesting adaptive responses in the kidney to excrete
phosphate. We also found that GPRC6A
2/2 mice had mild but
significant increases in urinary calcium and phosphate excretion
(calcium/creatinine ratio: 0.1960.02; phosphorus/creatinine ra-
tio: 5.3260.31) compared to wild-type controls (calcium/creati-
nine ratio: 0.1360.01; phosphorus/creatinine ratio: 3.9360.28)
(Table 1). The mild hypercalciuria was not evident at 6-weeks-of-
age, but was present at subsequent ages, whereas the increased
urinary phosphate levels were observed only in 16-week old
GPRC6A
2/2 mice. The level of serum phosphorus was also
significantly higher in 16 week-old knockout mice
(6.5260.18 mg/dl) compared to wild-type littermates
(5.1860.21 mg/dl) (Table 1). Circulating concentrations of
calcium, PTH, FGF23, and 1,25(OH)2 vitamin D levels were
not significantly different between wild-type and GPRC6A
2/2
mice (Table 1). In addition, we found that urinary protein
excretion was elevated in GPRC6A
2/2 mice by Western blot
analysis (Fig. 4E). Immunohistochemical analysis revealed that this
protein band in the urine represents b2-microglobulin (Fig. 4F),
providing evidence for abnormalities in the proximal tubule
function in GPRC6A null mice.
Metabolic Abnormalities in GPRC6A Deficient Mice
We also found that the liver of GPRC6A
2/2 mice exhibited
histological features of hepatic steatosis by H&E and Oil Red O
staining (Fig. 5A). Lipid positive droplets were present in
hepatocytes of GPRC6A
2/2 mice but not wild-type mice. This
correlated with increased triglyceride content in the livers of
GPRC6A
2/2 mice (Fig 5B). In addition, we found that fasting
serum glucose levels were significantly greater and insulin levels
were lower in GPRC6A
2/2 mice compared to wild-type littermates
(Table 1). Since fatty liver disease is a manifestation of ‘‘metabolic
syndrome’’, we examined GPRC6A
2/2 mice for evidence of
glucose intolerance. We performed glucose tolerance tests
following IP injection of glucose (2 g/kg of body weight) after an
overnight fast (GTT), and insulin tolerance tests by IP injection of
insulin (0.2 units/kg of body weight) after 6 hours fast (ITT).
These tests revealed that GPRC6A
2/2 mice had a significantly
higher serum glucose levels during the GTT and lower sensitivity
to insulin than wild-type mice in the ITT (Fig. 5C and D,
respectively).
Musculoskeletal Phenotype of GPRC6A Deficient Mice
Both male and female GPRC6A
2/2 mice had a significant
reduction in lean body mass compared to wild-type littermates
(7.9%and 10% inmaleand 11.2%and 13% infemale GPRC6A
2/2
mice at 12 and 16 weeks, respectively) as assessed by PIXImus
TM
densitometry (Fig. 6A). There were no apparent differences,
however, in muscle histology between wild-type and GPRC6A
2/2
mice (data not shown). Body fat as assessed by PIXImus
TM
densitometry (Fig. 6B) and white fat by gross inspection of various
organs, such as testis, were increased in GPRC6A
2/2 compared to
wild-type mice. Both male and female GPRC6A
2/2 mice did not
have the expected age-dependent increase in bone mineral
density (BMD). Indeed, BMD was significantly less at 8, 12, and
16 weeks-of-age in GPRC6A
2/2 mice as compared to age-matched
wild type mice (p,0.05) (Fig. 6C). To determine if the decreased
bone density might be due to defective mineralization of bone, we
performed backscatter EM and bone histological analysis. Back-
scatter EM of cortical bone demonstrated diminished mineraliza-
tion surrounding osteocyte lacunae and on the perisoteal and
endosteal surfaces (Fig. 6D). Qualitative analysis of bone histology
also revealed an increase in unmineralized osteoid surfaces (Fig. 6E)
Table 1. Serum and urinary biochemistries from GPRC6A
+/+ and GPRC6A
2/2 mice at age of 16 week old.
GPRC6A
+/+ GPRC6A
2/2
Serum Calcium (mg/dl)
a 8.2360.1 8.2760.19
Phosphorus (mg/dl) 5.1860.21 6.5260.18**
FGF23 (pg/ml) 74.5168.24 89.09610.71
PTH (pg/dl) 50.667.96 50.2664.91
1,25(OH)2 Vit D3 (mg/dl) 366.17698.06 251.35638.56
TRAP (U/L) 4.6660.55 5.2560.74
Insulin (ng/ml) 1.7860.2 0.9460.15*
Glucose (mg/dl)
b 131.6760.33 168.3367.33*
Cholesterol (mg/dl)
c 170.5163.38 181.2765.27
Osteocalcin (ng/ml)
c 70.7565.35 58.0765.99
Testosterone (ng/ml)
c 1.2560.42 0.1960.05*
Estradiol (pg/ml)
c 16.468.59 57.95617.17*
LH (ng/ml)
c 0.5860.36 1.5260.5
FSH (ng/ml)
c 37.362.24 42.8466.3
Urine Dpd/Creatinine (mg/mg) 10.0761.29 10.7361.39
Calcium/Creatinine Ratio (mg/mg) 0.1360.01 0.1960.02*
Phosphorus/Creatinine Ratio (mg/mg) 3.9360.28 5.3260.31**
Protein/Creatinine Ratio (mg/mg) 15.3261.83 22.6562.37*
aSerum calcium were measured at 8 week-old mice. Data are mean6SEM from more than 10 individual mice in each group.
bGlucose was measured total blood after over night fasting from more than four mice of GPRC6A
+/+ and GPRC6A
2/2 male mice, respectively.
cSerum osterocalcin, testosterone, estradiol, LH and FSH were measured from more than six mice of GPRC6A
+/+ and GPRC6A
2/2 male mice, respectively.
*and
** Significant difference from GPRC6A
+/+ and GPRC6A
2/2 mice at p , 0.05 and p , 0.01 respectively.
doi:10.1371/journal.pone.0003858.t001
Effects of GPRC6A Deficiency
PLoS ONE | www.plosone.org 4 December 2008 | Volume 3 | Issue 12 | e3858and diffuse calcein labeling of bone compared to the distinct double
labels in wild-type mice (Fig. 6F), indicative of impaired mineral-
ization.
Discussion
Recent data indicate that energy, fat, bone, and glucose
metabolism are interrelated through novel hormonal regulatory
pathways [20]. We observed a complex phenotype in GPRC6A
2/2
mice consisting of defective mineralization of bone and impaired
osteoblast function in male and female mice, a decrease in lean
body mass, an increase in fat mass, hyperphosphatemia and
hypercalciuria, hyperglycemia and feminization of male mice
associated with altered ratio of estradiol and testosterone,
suggesting that GPRC6A participates in hormonal control of
energy metabolism. Multiple organs and metabolic functions were
affected by ablation of GPRC6A in mice.
Obesity-dependent metabolic syndrome is associated with
impaired glucose tolerance and hepatic steatosis [27]. Similarly,
GPRC6A
2/2 mice had elevated serum glucose levels (Table 1)
glucose intolerance, insulin resistance and hepatic steatosis, as
evidence by histological presence of fat and biochemical evidence
of increase triglyceride content in livers of knockout mice (Fig. 5).
The presence of a metabolic-like syndrome in GPRC6A
2/2 mice
suggests that this receptor regulates metabolic pathways involved
in glucose and fat metabolism, although these studies do not define
the exact target organ of GPCR6A effects or whether this is a
direct effect of GPRC6A or an indirect effect related to insulin
resistance in GPRC6A
2/2 mice. Recently, osteocalcin produced by
bone has been shown to be a circulating hormone that targets the
pancreas to increase insulin secretion and adipocytes to increase
adiponectin production [28]. Osteocalcin (Oc) has also been
shown to target an unknown Gai coupled GPCR [29] and can
activate GPRC6A in the presence of extracellular calcium [3].
These observations raise the possibility that GPRC6A, might
mediate some of the actions of Oc in vivo and provide a molecular
pathway linking bone and energy metabolism. Future studies will
be needed to determine if this receptor mediates the effects of
Figure 3. Possible mechanisms underlying altered testosterone/estrogen ratio in GPRC6A
2/2 male mice. (A and B) RT-PCR and real-time
RT-PCR analysis of androgen receptor (AR) expression. AR expression in testis (Te) and bone marrow (BM) was not different between GPRC6A
+/+ and
GPRC6A
2/2 male mice. (C) Real time RT-PCR analysis of aromatase expression in testis. (D and E) Comparison of the aromatase protein expression in
testis from GPRC6A
+/+ and GPRC6A
2/2 male mice. Small increments in aromatase protein expression were observed in GPRC6A
2/2 male mice by
Western blot analysis (D) that was localized by immunhistochemistry (E) to Leydig cells (L, arrow head) and to a lesser degree in sertoli cells (SC), and
spermatogonia (SG) (respectively indicated by arrows). (F and G) Real time RT-PCR analysis of Cyp17 and Sult1e1 expression in testis. (H and I) RT-PCR
and real-time RT-PCR analysis of GnRH expression in brain.
doi:10.1371/journal.pone.0003858.g003
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underlying insulin resistance and hepatic steatosis in GPRC6A
2/2
mice.
Another phenotype was feminization of male GPRC6A
2/2
mice. Low testosterone levels acting observed in GPRC6A null
mice, through classical genomic mechanisms, could explain the
feminization of GPRC6A null mice. The phenotype of GPRC6A
null mouse resembles, but is less severe than, the AR null and Tfm
(Testicular feminized) mouse models [21,23]. GPRC6A null mice,
however, have inappropriately normal LH and FSH levels and
increased estrogen, whereas the disruption of the genomic actions
of AR is associated with increased LH and FSH and low estradiol
levels [30]. Our studies do not define the mechanism of the altered
testosterone/estrogen ratio. The alterations in circulating sex
steroid levels in GPRC6A null mice might result from direct actions
of the receptor to regulate testosterone biosynthesis or conversion
to estrogens in the testis or other tissue, and/or to an indirect effect
through potential GPRC6A regulation of the hypothalamus or
pituitary gland. The observation that GPRC6A is expressed in the
hypothalamus (GEO accession GDS565), gonadotrope cells of the
anterior pituitary (GEO accession GDS2167), sertoli cells (GEO
accession GDS222) and testes (GEO accession GDS2098) as well
as the slight increase in level of aromatase protein expression in
testis support both possibilities [2,3,14]. Testosterone replacement
in GPRC6A
2/2 mice, measurement of aromatase activity and
steroid biosynthesis, and assessment of GPRC6A function in other
tissues will all be needed to establish the biological significance and
mechanism of the observed reduction in testosterone levels in these
mice.
The predominant effect of GPRC6A deficiency in bone was to
impair bone mineralization. It is not clear whether these bone
abnormalities represent a direct effect of GPRC6A loss from
osteoblasts or secondary effects due to potential actions of the
concomitant sex steroid hormone abnormalities on bone remod-
eling. But testosterone deficiency typically leads to increased
osteoclast-mediated bone resorption [31], which was not observed
in these animals. Further studies will be needed to determine the
relative contribution of secondary alterations in sex hormones and
primary loss of calcium-sensing receptor responses to the observed
bone phenotype in GPRC6A null mice. Regardless, the expression
of GPRC6A in bone and osteoblasts and the resulting bone
phenotype raises the possibility that GPRC6A is a candidate for
the novel osteoblastic calcium-sensing receptor [3,15]. that is
distinct from CASR [15].
With regard to the kidney, we observed that GPRC6A is
expressed in both proximal and distal tubules and the ablation of
Figure 4. GPRC6A deficiency is associated with a renal phenotype. (A) Expression of GPRC6A messenger in kidney by in-situ hybridization
showing localization of both proximal and distal tubular segments. (B-D) Kidney expression of NaPi IIa. Immunohistochemistry (B) demonstrates
decreased Napi IIa protein expression and translocation to the brush border membrane in GPRC6A
2/2 mice. Loss of GPRC6A also resulted in
decreased Napi IIa message expression by RT-PCR (C) and real-time RT-PCR analysis (D). Data represent the mean6SEM from 6 to 10 mice in each
group. * indicates a significant difference from GPRC6A
+/+ and GPRC6A
2/2 mice at p,0.05, respectively. (E and F) Low molecular weight proteinuria in
GPRC6A
2/2 mice. Western-blot analysis using 4–12% SDS-Page gel and comasis blue staining identified an increase in urinary excretion of a low
molecular weight protein in GPRC6A
2/2 mice (E) that was identified as b2-mcroglobulin by immunobloting with an anti-b2-mcroglobulin antibody
(F). The arrow indicates b2-mcroglobulin.
doi:10.1371/journal.pone.0003858.g004
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phosphate, and b2-microglobulin. The effects of GPRC6A loss of
function on urinary calcium excretion is opposite to the
hypocalcuria caused by inactivating mutations of the related
calcium sensing receptor CASR [32]. It is not clear from our
studies if these renal abnormalities associated with disruption of
GPRC6A function are direct or indirect. We failed to observe in
GRPC6A null mice evidence of secondary increase PTH or
increased bone turnover that would be expected if GPRC6A
ablation resulted in a renal calcium leak. Theoretically, a primary
decrease in bone formation and decreased buffering capacity for
calcium, with consequent increased urinary expression of dietary
calcium could account for the relationship between osteopenia and
hypercalciuria in GPRC6A
2/2 mice. Alternatively, a primary effect
of GPRC6A to regulate gastrointestinal phosphate transport
would be another possible explanation for increased serum and
urinary phosphate. There are some enigmatic clinical disorders
with features similar to the GPRC6A
2/2 mice that support the
possibility of coordinated effects between bone formation and
renal conservation of calcium. In this regard, a subset of male
patients with idiopathic osteoporosis and nephrolithiasis have the
combined features of decreased osteoblast-mediated bone forma-
tion and hypercalciuria, without evidence of hypogonadism,
secondary hyperparathyroidism, or abnormal vitamin D levels
[33] [34]. It will be interesting to determine if gene polymorphisms
of GPRC6A are associated with osteopenic and hypercalciuric
clinical disorders. The observed reduction of NaPi IIa in
GPRC6A
2/2 mice and the low molecular weight proteinuria is
consistent with a primary proximal tubular defect. The increase in
serum phosphate in GPRC6A
2/2 is unexplained.
In summary, we have shown that GPRC6A has multiple
functions as evidenced by abnormalities in GPRC6A null mice that
include alterations in circulating testosterone and estrogen levels
and feminization of male mice, defects of bone density and bone
cell function and abnormalities in the renal handling of calcium
and phosphate, hyperglycemia and liver steatosis. The ligand
profile of GPRC6A, which includes extracellular calcium,
calcimimetics, amino acids, and osteocalcin [2,3,14,20], along
with the complex phenotype of GPRC6A null mice suggests that
GPRC6A may represent an anabolic receptor that responds to a
variety of nutritional and hormonal signals and may serve to
coordinate the functions of multiple organs in response to changes
of these ligands.
Materials and Methods
Generation of GPRC6A Knockout Mice
The GPRC6A-deficient mouse model was created by replacing
exon 2 of the GPRC6A gene with the hygromycin resistance gene
(Fig. 1). To generate the targeting construct, the hygromycin
resistance gene under the control of the PGK promoter was cloned
into the Sma Ia n dEco RV sites of pBS-lox, which was produced by
Figure 5. GPRC6A deficiency is associated with a liver phenotype. (A) Histological examination of liver from GPRC6A
2/2 male mice at age of
16 week old by H & E stained (left panel), Oil Red O stained (right panel). (B) Hepatic triglyceride levels in GPRC6A
+/+ and GPRC6A
2/2 male mice at age
of 16 week old. Liver triglyceride levels were expressed as mg/g liver tissue. (C and D) GTT (C) and ITT (D) in 3 month-old male GPRC6A
+/+ and
GPRC6A
2/2 mice. ITT data are presented as percentage of initial blood glucose concentration. Data represent the mean6SEM from more than 5 male
mice in each group. * Significant difference from GPRC6A
+/+ and GPRC6A
2/2 mice at p,0.05.
doi:10.1371/journal.pone.0003858.g005
Effects of GPRC6A Deficiency
PLoS ONE | www.plosone.org 7 December 2008 | Volume 3 | Issue 12 | e3858cloning the oligonucleotide Lox71: 59-ctagataccgttcgtatagcatacatta-
tacgaagttatg-39 into the Xba Ia n dBam HI sites and the
oligonucleotide Lox 66: 59-agcttataacttcgtatagcatacattatacgaacgg-
tag-39 into the HindI I Ia n dSal I sites of pBluescript (Stratagene),
to produce pBS-lox-PGK-Hyg. A genomic fragment from intron 1 of
GPRC6A gene, representing the 59 homologous targeting region, was
amplified by PCR using Advantage 2 Taq polymerase (BD
Biosciences) and primers PP 232-Avr: 59-aaacctagggccattcat-
gaaaaaatgttgtcctcagatgaccatcc-39, and PP 233-Avr: 59-aaacctaggct-
cactcaacccccatgtccttccaactctagctg-39, digested with Avr II, and cloned
into the Xba I site of pBS-lox-PGK-Hyg to produce pBS-GPRC6A-
Intron 1. A genomic fragment from intron 2 of GPRC6A,representing
the39homologoustargetingregion,wasthenamplifiedbyPCRusing
Advantage 2 Taq polymerase and primers 298: 59-aaagtcgaccta-
cattggtccatcgattacattagttcttgg-39 and PP 299: 59-aaagtcgacgaggcctt-
gaggtcaaactccagaaccccagag-39, digested with Sal I ,a n dc l o n e di n t o
the Sal I site of pBS-GPRC6A-Intron I to produce pGPRC6A-KO.
The methods for knocking out the GPRC6A gene have been described
previously in detail [35]. Briefly, the mouse embryonic cell line RW-
4, derived from 129X1/SvJ mouse strain[36] and kindly provided by
Stephan Teglund at the Karolinska Institute Center for Transgene
Technologies, was transfected by electroporation with Not Il i n e a r i z e d
pGPRC6A-KO. Hygromycin resistant embryonic stem cell colonies
were picked, expanded, and tested by PCRto identify clones in which
the PGK-Hygromycin gene had correctly replaced exon 2 of the
GPRC6A gene. The correctly mutated embryonic stem clones were
injected into blastocysts derived from C57BL/6 3.5 days after mating
andimplantedintoB6CBAF1pseudopregnantfemales.Theresulting
male chimeras were bred with female C57BL/6 mice. Homozygous
founders were generated by mating the resulting heterozygous mice.
The successful targeting of GPRC6A in embryonic stem (ES) cells was
confirmed by Southern blot analysis of the genomic DNA from ES
cell clones. We observed no apparent differences in the founders
generated from different ES cell clones. We focused our studies on
founder line 17.
Mice were maintained and used in accordance with recom-
mendations as described (National Research Council. 1985) Guide
for the Care and Use of Laboratory Animals DHHS Publication
NIH 86-23 , Institute on Laboratory Animal Resources, Rockville,
MD) and following guidelines established by the University of
Kansas Medical Center Institutional Animal Care and Use
Committee.
PCR primers
The following intron-spanning primersetswere used forRT-PCR:
mGPRC6A.24.For: ccagaaagatggccctattga; mGPRC6A.1754.Rev:
ctccttactggggcccagtggg; mAndR.F578: caacttgcatgtggatgacc and
mAndR.R961: cttgagcaggatgtgggattc. mGnRH.For169: agcactggtcc-
tatgggttg and mGnRH.Rev389: gggccagtgcatctacatct. NaPiII.F248:
ccacctatgccatctccagt and NaPiII.R635: accatgctgacaatgatgga;
mALP.905F: aacccagacacaagcattcc and mALP.1458R:
ctgggcctggtagttgttgt, G3PDH.F143: gaccccttcattgacctcaactaca;
G3PDH.R1050: ggtcttactccttggaggccatgt for control RNA loading.
The following primer sets were used for real-time PCR: aromatase
forward primer: tgagaacggcatcatatttaacaac and reverse primer:
gcccgtcagagctttcataaag; Cyp17 forward primer: tggaggccactatccgagaa
and reverse primer: tgttagccttgtgtgggatgag; and Sult1e1 forward
primer: tcatgcgaaagggaattatagga and reverse primer: tgcttgtagtgct-
catcaaatctct.
RT-PCR and Real-Time RT-PCR
RT-PCR was performed using two-step RNA PCR (Perkin-
Elmer) as previously described [3]. Specific intron-spanning
Figure 6. Characterization of the bone phenotype of GPRC6A
2/2 mice. (A–C) Comparison of the lean body mass (A), fat content (B) and bone
mineral density of the femur analysis (C) by PIXImus
TM analysis in GPRC6A
+/+ and GPRC6A
2/2 mice at ages ranging from 6 to 16 weeks. Data represent
the mean6SEM from 6 to 10 mice in each group. * Significant difference from GPRC6A
+/+ and GPRC6A
2/2 mice at p,0.05. (D) Backscattered Scanning
Electron Microscopy analysis of tibia cortical bone in 16-week-old GPRC6A
+/+ (upper panel) and GPRC6A
2/2 mice (lower panel). The arrows showed
the diminished mineralization layer in the bone of GPRC6A
2/2 mice. (E) Toluidine blue-stained plastic sections of femur from 16-week-old GPRC6A
+/+
(upper panel) and GPRC6A
2/2 mice (lower panel). The arrows showed the unmineralized osteoid surfaces in the bone of GPRC6A
2/2 mice. (F) Plastic
unstained sections of tibia cortical bone viewed under fluorescent light in 16-week-old GPRC6A
+/+ (upper panel) and GPRC6A
2/2 mice (lower panel)
prelabeled with twice calcein (double label).
doi:10.1371/journal.pone.0003858.g006
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quantitative real-time RT-PCR assessment of bone markers
expression, we isolated and reverse transcribed 2.0 mg total
RNA from long bone of 8-week-old mice as previously described
[37]. For quantitative real time RT-PCR assessment of aromatase,
CYP17 and Sutl1e1 genes expression we isolated and reverse
transcribed total RNA isolated from testis, brain, fat, liver and
pituitary of 33 week-old GPRC6A
+/+ (n=5) and GPRC6A
2/2 mice
(n=5) as previously described [38] using specific primer sets. For
expression of AR, GnRH and NaPi IIa, the oligo primers sequences
were obtained from Primer Bank, a public resource for PCR
primers (pga.mgh.harvard.edu/primerbank/) [39], and the thresh-
old cycle (Ct) of tested-gene product from the indicated genotype
was normalized to the Ct for cyclophilin A as we have previously
described [37].
Cell Culture and Western Blotting
HEK-293 cells were co-transfected with pcDNA3.mGPRC6A or
pcDNA3 plasmid as previously described [3]. An anti-peptide
antibody was raised in a rabbit against a peptide (AI-
HEKMLSSDDHPRRPQIQKC) corresponding to a sequence in
the extracellular domain of mouse GPRC6A (in exon 1 of mouse
GPRC6A gene) produced by Abgent (San Diego, CA). For phospho-
ERK, the phospho-ERK1/2 levels were determined by immuno-
blotting using anti-phospho-ERK1/2 mitogen-activated protein
kinase antibody (Cell Signaling Technology) [3]. Urinary b2-
mcroglobulin was detected by rabbit polyclonal anti-b2-mcroglo-
bulin antibody (Abcam Inc.). For aromatase expression analysis, the
rabbit polyclonal anti-aromatase antibody (Abcam Inc.) and goat
anti-rabbit IgG HRP secondary antibody (Santa Cruz Biotechnol-
ogy Inc.) were used. Mouse anti-Actin antibody (Santa Cruz
Biotechnology Inc.) was used for control protein loading.
PIXImus
TM Bone Densitometer Analysis and Bone
Histology
Bone mineral density (BMD) of whole skeletons and femurs
were assessed at 6, 8, 12, and 16 weeks of age using a PIXImus
TM
bone densitometer (Lunar Corp.) as previously described [32].
Skeletons of mice were performed as reported previously by our
laboratory [32].
Backscattered Scanning Electron Microscopy
Plastic embedded bone from 8 week-old wild-type and GPRC6A
knockout mice were cut and polished, and mounted on aluminum
sockets with bone surface facing above, sputter-coated with gold
and palladium, and examined with field emission scanning
electron microscopy (Philips XL30, FEI Company) equipped with
a backscatter electron imaging system.
Immunohistochemistry
Wild-type and GPRC6A mouse kidney were routinely pro-
cessed and embedded in paraffin. The paraffin sections at
thickness of 5 mm were prepared and collected on commercially
available, positively charged glass slides (Superfrost Plus, Fisher
Scientific). The sections were dried on a hot plate to increase
adherence to the slides. Representative sections were de-paraffined
and re-hydrated through conventional methods. The sections were
digested by 10 mg/ml hyaluronidase for 20 min. Nonspecific
protein binding was blocked by incubation with 10% normal goat
serum. The sections were incubated in polyclonal rabbit against
mouse NaPi IIa (1:500 dilution) or polyclonal goat anti-human
aromatase antibody (1:200 dilution) (CYP19, Santa Cruz Biotech-
nology, Inc.) at 4uC overnight. The negative control sections were
incubated with 0.01 M PBS. Thereafter, the sections were treated
sequentially with FITC-conjugated Donkey anti Rabbit IgG
secondary antibody (Jackson Labs). The nucleus was stained with
ready to use Hoechst (Sigma).
Whole-Mounts and Carmine Stain of Mammary Glands
Mice mammary fat pads were excised and fixed for a minimum
of 2 h in Carnoy’s solution (60% ethanol, 30% chloroform, and
10% glacial acetic acid). The fixed glands were washed in 70%
ethanol for 15 min and then rinsed in water for 5 min. The
mammary glands were stained overnight at 4uC in carmine alum
stain (1 g carmine and 2.5 g aluminum potassium sulfate in
500 ml water).
In Situ Hybridization
For GPRC6A gene expression, the probe was amplified by RT-
PCR using following intron spanning primer: mGPRC6A.189F (in
Exon I) cgggat ccagacgaccacaaatccag and mGPRC6A.539R
(spanned over Exon II and III) ccaagctt gattcataactcacctgtggc. After
RT-PCR, the product was subclone into pre-cutted by BamHIa n d
Hind III of pBluescript SK(+). Using T7 promoter will create sense
RNA, and T3 promoter will create Anti-sense RNA ribo-probe.
Serum and Urine Biochemical Measurements
Serum was collected using a retroorbital bleeding technique.
For urine samples collection, mice were placed in metabolic cages
(Hatteras Instrument), and urine was collected for 24 h. The urine
volume was measured before storage at 270uC.
Serum testosterone and estradiol levels were measured by
testosterone enzyme immunoassay test kit and estradiol (E2)
enzyme immunoassay test kit from BioCheck, Inc. Follicle
stimulating hormone (FSH) and luteinizing hormone (LH) were
measured by mouse FSH radioimmunoassay and the mouse LH
sandwich assay as described by the University of Virginia Center
for Research in Reproduction Ligand and Analysis Core (NICHD
(SCCPRR) Grant U54-HD28934). Serum and urinary Calcium
was measured by the colorimetric cresolphthalein binding method,
and phosphorus was measured by the phosphomolybdate–ascorbic
acid method [32]. Serum TRAP was assayed with the ELISA-
based SBA Sciences mouseTRAP
TM assay. Serum PTH and 1, 25
(OH)2 vitamin D were measured the kits from Immutopics, Inc.
and Immunodiagnostic system, Ltd., respectively. Serum Fgf23
levels were measured by using FGF-23 ELISA kit (Kainos
Laboratories Inc.) following the manufacturer’s protocol. Creat-
inine was measured by the colorimetric alkaline picrate method
(Sigma kit 555, Sigma-Aldrich). Urinary protein and Dpd were
measured by Bio-Rad and Metra Biosystems, Inc., respectively.
Metabolic Studies
For glucose tolerance test (GTT) glucose (2 g/kg body weight)
was injected intraperitoneally (IP) after an overnight fast, and blood
glucose was monitored using blood glucose strips and the Accu-
Check glucometer (Roche) at indicated times. For insulin tolerance
test (ITT) mice were fasted for 6 hr, injected IP with insulin (0.2 U/
kg body weight, Lilly Research Laboratories), and blood glucose
levels were measured at indicated times as described [20]. ITT data
are presented as percentage of initial blood glucose concentration.
Statistics
We evaluated differences between groups by one-way analysis of
variance. All values are expressed as mean6SEM. All computa-
tions were performed using the Statgraphic statistical graphics
system (STSC Inc.).
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